Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity

Burstein, 2005, AAPS J., 7, E143, 10.1208/aapsj070115 Perez-Reyes, 1985, 287 Schwilke, 2009, Clin. Chem., 55, 2180, 10.1373/clinchem.2008.122119 Doyle, 1990, Agents Actions, 31, 157, 10.1007/BF02003237 Burstein, 1992, J. Med. Chem., 35, 3135, 10.1021/jm00095a007 Zurier, 1998, Arthritis Rheum., 41, 163, 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9 Karst, 2003, JAMA, 290, 1757, 10.1001/jama.290.13.1757 Rhee, 1997, J. Med. Chem., 40, 3228, 10.1021/jm970126f Vann, 2006, J. Pharmacol. Exp. Ther., 320, 678, 10.1124/jpet.106.111625 Karst, 2007, J. Pharmacol. Exp. Ther., 322, 420, 10.1124/jpet.107.124214 Burstein, 2004, Arthritis Rheum., 50, 4078, 10.1002/art.20805 Salim, 2005, Neuropharmacology, 48, 1164, 10.1016/j.neuropharm.2005.02.010 Pertwee, 1972, Br. J. Pharmacol., 46, 753, 10.1111/j.1476-5381.1972.tb06900.x Wiley, 2003, Eur. J. Pharmacol., 471, 185, 10.1016/S0014-2999(03)01856-9 Loev, 1973, J. Med. Chem., 16, 1200, 10.1021/jm00269a002 Dyson, 2005, Pain, 116, 129, 10.1016/j.pain.2005.03.037 Stebulis, 2008, Life Sci., 83, 666, 10.1016/j.lfs.2008.09.004 Mitchell, 2005, Neurosci. Lett., 382, 231, 10.1016/j.neulet.2005.03.019 Machado, 2014, Br. J. Pharmacol., 171, 961, 10.1111/bph.12488 Yang, 2012, Future Med. Chem., 4, 187, 10.4155/fmc.11.179